Margaret Olinger - 12 Jul 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Chief Commercial Officer
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol: AMLX
Transactions as of: 12 Jul 2023
Net transactions value: +$7,400
Form type: 4
Filing time: 14 Jul 2023, 16:20:33 UTC
Previous filing: 24 May 2023
Next filing: 29 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Options Exercise	$7,400	+20,000	+8.7%	$0.3700^*	251,108	12 Jul 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (Right to Buy)	Options Exercise	$0	-20,000	-22%	$0.000000	69,577	12 Jul 2023	Common Stock	20,000	$0.3700	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of the date of this filing, 67,156 shares subject to the option are vested and exercisable. 2,421 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023.